- Home
- NBIX vs CYBR Comparison
NBIX vs CYBR Comparison
Compare NBIX & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- CYBR
- Stock Information
- Founded
- NBIX 1992
- CYBR 1999
- Country
- NBIX United States
- CYBR Israel
- Employees
- NBIX 1448
- CYBR N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- CYBR Computer Software: Prepackaged Software
- Sector
- NBIX Health Care
- CYBR Technology
- Exchange
- NBIX Nasdaq
- CYBR Nasdaq
- Market Cap
- NBIX 11.8B
- CYBR 12.4B
- IPO Year
- NBIX 1996
- CYBR 2014
- Fundamental
- Price
- NBIX $117.44
- CYBR $305.27
- Analyst Decision
- NBIX Buy
- CYBR Strong Buy
- Analyst Count
- NBIX 24
- CYBR 29
- Target Price
- NBIX $163.91
- CYBR $327.10
- AVG Volume (30 Days)
- NBIX 1.0M
- CYBR 558.4K
- Earning Date
- NBIX 10-30-2024
- CYBR 11-13-2024
- Dividend Yield
- NBIX N/A
- CYBR N/A
- EPS Growth
- NBIX 97.40
- CYBR N/A
- EPS
- NBIX 3.73
- CYBR 0.27
- Revenue
- NBIX $2,242,800,000.00
- CYBR $909,462,000.00
- Revenue This Year
- NBIX $26.97
- CYBR $27.72
- Revenue Next Year
- NBIX $16.69
- CYBR $23.19
- P/E Ratio
- NBIX $31.50
- CYBR $1,050.02
- Revenue Growth
- NBIX 25.72
- CYBR 30.31
- 52 Week Low
- NBIX $108.14
- CYBR $185.04
- 52 Week High
- NBIX $157.98
- CYBR $318.16
- Technical
- Relative Strength Index (RSI)
- NBIX 42.69
- CYBR 62.39
- Support Level
- NBIX $119.08
- CYBR $288.00
- Resistance Level
- NBIX $129.67
- CYBR $318.16
- Average True Range (ATR)
- NBIX 3.34
- CYBR 10.62
- MACD
- NBIX -0.02
- CYBR 1.56
- Stochastic Oscillator
- NBIX 14.59
- CYBR 72.27
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader within that subsegment, with more than half of the Fortune 500 CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While historically, CyberArk has sold its security solutions primarily via on-premises licenses, over the past few years, it has transitioned to a subscription, recurring revenue model.